GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (STU:RFS) » Definitions » Other Stockholders Equity

Resverlogix (STU:RFS) Other Stockholders Equity : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Resverlogix Other Stockholders Equity?

Resverlogix's Other Stockholders Equity for the quarter that ended in Sep. 2024 was €0.00 Mil.

Resverlogix's quarterly Other Stockholders Equity increased from Mar. 2024 (€-0.00 Mil) to Jun. 2024 (€0.00 Mil) but then declined from Jun. 2024 (€0.00 Mil) to Sep. 2024 (€0.00 Mil).

Resverlogix's annual Other Stockholders Equity increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) but then declined from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).


Resverlogix Other Stockholders Equity Historical Data

The historical data trend for Resverlogix's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Other Stockholders Equity Chart

Resverlogix Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.09 1.37 - - -

Resverlogix Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Resverlogix Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity


Resverlogix Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Resverlogix's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Resverlogix Business Description

Traded in Other Exchanges
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Resverlogix Headlines

No Headlines